{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5575","upperLimit":"0.6934","value":"0.6255"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"}],"units":"Participants"}],"description":"Compare 4-year EFS using eligible participants only to the historical rate of 0.65 with IRSI-V. The 4-year EFS is probability of no relapse, secondary malignancy, or death after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.65.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40;dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"OG000","title":"Vincristine, Dactinomycin, Cyclophosphamide (VAC)"}],"paramType":"NUMBER","populationDescription":"17 ineligible participants were excluded.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison","type":"SECONDARY","unitOfMeasure":"Probability"}